Metropolitan Bank Holding Corp. heads into its Q2 print on July 21 with a striking divergence: options traders have rarely been this bullish, while insiders have spent the past several weeks selling into strength.
The options signal is the sharpest data point in the setup. The put/call ratio collapsed to 0.21 on July 20 — nearly 1.75 standard deviations below its 20-day average of 1.11, and close to the lowest reading of the past year. That means call buying is dominant to a degree that is historically unusual for MCB. The stock has quietly drifted higher, up 5.8% over the past month and 1.4% on the week to $98.55, while correlated regional peers — LOB, STBA, HBNC — each slipped between 1.3% and 2.8% on the prior session. MCB held flat on that same day, which adds modest relative strength to the setup. Borrow conditions carry no meaningful signal in either direction: availability is extremely loose at roughly 3,940%, and cost to borrow is just 0.46% despite rising about 47% over the past week from a very low base.
Insider activity tells a different story. The heaviest selling came from director Robert Patent, who shed 15,000 shares across two transactions in early June for proceeds of roughly $1.4 million. An EVP also made a series of small sales in late June and early July. Against that, CFO Daniel Dougherty purchased 1,000 shares at $79.95 back in March — now well below current levels. Net insider activity over the trailing 90 days works out to net selling of roughly $1.9 million. On a small-float regional bank trading near its 52-week high, that pattern of director and executive selling into the rally is worth noting, even if none of the individual transactions are large enough to constitute a definitive signal.
The analyst setup is mildly constructive. Keefe Bruyette raised its target to $109 in April while maintaining an Outperform rating, and UBS initiated with a Neutral and a $97 target around the same time. The mean target across the consensus is $112.67, implying roughly 14% upside from current levels — though the stock has already run well past the UBS entry point. Valuation looks undemanding: the P/E is around 9.1x and price-to-book sits at 1.14x, both having edged higher over the past month as the stock rallied. Short interest, at 6% of the free float and up roughly 15% over the past week, has been rising — but borrow demand has not meaningfully tightened, suggesting the increase reflects repositioning rather than a conviction short thesis building. The ORTEX short score of 42.6, while drifting higher over the past ten days, remains in the lower half of its recent range.
The print will test whether MCB's loan growth, deposit costs, and credit quality in its New York metro footprint can justify both the stock's proximity to 52-week highs and the unusual concentration of call activity heading into the release.
See the live data behind this article on ORTEX.
Open MCB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
